证券研究报告 固态中试线加速落地，各材料环节全面升级 ── 固态电池行业深度 2025年9月10日 行业评级：看好 分析师 邱世梁 邮箱 qiushiliang@stocke.com.cn 证书编号 S1230520050001 分析师 黄华栋 邮箱 huanghuadong@stocke.com.cn 证书编号 S1230522100003 研究助理 彭沈楠 投资要点 1、固态电池：2027年系技术实现节点，2030年或迈向产业化 固态电池具备本征安全性与极高能量密度，有望成为动力电池终极技术路线。硫化物全固态电池为当前国内外最重视路线，预计国内在2027年突 破电解质技术链，后续先后优化负极和正极，2030年迈向规模化。国内政策大力支持固态电池发展，电池和新能车龙头全面布局。 2、固态电解质：硫化物为当前热点，远期看好复合电解质 95% 路线各具优劣，无机物(硫化物、氧化物、卤化物)电解质具备高离子电导率和宽电化学窗口优势；聚合物电解质柔韧性好，可改善界面接触；复 合物电解质可结合两者优势，远期有望成为最佳路线。当前硫化物电解质规模化难点在硫化锂降本，此外干法工艺的粘结剂也待优化。 3、正负极材料：短期主 ...

证券日报网讯 9月8日晚间，长阳科技发布公告称，公司计划于2025年09月16日下午15：00-16：00举行 2025年半年度业绩说明会。 （文章来源：证券日报） ...

证券代码：688299 证券简称：长阳科技 公告编号：2025-046 宁波长阳科技股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 09 月 16 日（星期二）下午 15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 投资者可于 2025 年 09 月 09 日（星期二）至 09 月 15 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@solartrontech.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 宁波长阳科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 27 日发 布公司 2025 年半年度报告及摘要，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 ...

Group 1 - Shengtun Mining plans to repurchase shares worth between 500 million and 600 million yuan, with a maximum repurchase price of 11.82 yuan per share, aimed at employee stock ownership plans or equity incentives [1] - Kangnbei received a drug registration certificate for Linggui Shugan Granules, which is derived from traditional Chinese medicine and is used for treating phlegm and dampness due to Yang deficiency [2] - Zhangjiang Hi-Tech intends to publicly transfer 100% equity and related debts of Shanghai Jixin Rui Construction Technology Co., Ltd. with a total price not less than 151 million yuan [3] Group 2 - Shankai Intelligent won a bid for a metering device procurement project worth 13.318 million yuan from Hohhot Water Supply Company [4] - Hason Co. plans to jointly establish a supply chain company with a registered capital of 10 million yuan, in which Hason will hold a 10% stake [5] - Pudong Construction's subsidiaries won multiple major projects with a total amount of 1.271 billion yuan [6] Group 3 - Jinling Pharmaceutical received approval for the Phase III clinical trial of Olaratogrel tablets, which are used for treating moderate to severe pain associated with endometriosis [8] - Menohua's subsidiary obtained a drug registration certificate for Mosapride Citrate Tablets, aimed at improving gastrointestinal symptoms [10] - Shapuaisi's major shareholder plans to reduce holdings by up to 2% of the company's shares due to personal financial needs [11] Group 4 - Changyuan Power reported an August electricity generation of 3.771 billion kWh, a year-on-year decrease of 6.03% [15][16] - Xibu Livestock's August fresh milk production increased by 4.8% month-on-month but decreased by 7.27% year-on-year [19] - Yong'an Pharmaceutical's actual controller and chairman had their detention lifted, allowing them to resume normal duties [20] Group 5 - Jinkai Intelligent's director resigned due to work adjustments [22] - Xinhua Medical received a Class II medical device registration for an endoscope cleaning workstation [23] - Haishi Science and Technology's innovative drug HSK47388 received approval for a new indication clinical trial [25] Group 6 - Baotai Co. plans to participate in a land use rights auction in Baoji City with a starting price of 57.34 million yuan [26] - Minfeng Special Paper received a government subsidy totaling 11.2 million yuan [27] - Jiuchang Bio obtained a medical device registration for a heparin-binding protein assay kit [29] Group 7 - Jingao Technology plans to repurchase shares worth between 200 million and 400 million yuan, with a maximum price of 17.36 yuan per share [31] - Youxunda won a bid for a metering equipment project from China Southern Power Grid worth approximately 161 million yuan [32] - Qianli Technology reported an August vehicle sales increase of 168.55% year-on-year [32] Group 8 - Guangzhou Port expects an August container throughput increase of 1.2% year-on-year [32] - Kexing Pharmaceutical's GB08 injection completed the first subject enrollment for Phase II clinical trials [33] - Wu Ming Pharmaceutical plans to transfer 98.9% of its subsidiary's shares to a newly established wholly-owned subsidiary [34] Group 9 - Shanghai Electric's acquisition of K-Electric Limited shares has not yet completed the transfer [35] - Fulai New Materials plans to raise no more than 710 million yuan through a private placement [36] - Huaren Health's drug registration application for a new type of potassium ion competitive acid blocker has been accepted [37]

Summary of Key Points Core Viewpoint - Investor Zhang Jianping has gained significant attention in the market due to his successful investments in the AI and robotics sectors, with a total holding value of 5.096 billion yuan across nine A-share listed companies as of June 30 this year [1]. Group 1: Investment Performance - Zhang Jianping's investments in several stocks have seen remarkable price increases, with some stocks rising over 200% and 100% this year [1]. - Notable stocks include: - Cambrian (寒武纪-U) with a market value of 3.661 billion yuan and a year-to-date increase of 124.92% [2]. - Zhejiang Rongtai, which has surged 287% this year, with a market value of 505 million yuan [3][4]. - Rongtai shares have seen a 10% increase on September 2 [2]. - Longxi shares have increased by approximately 196% this year [6]. Group 2: Sector Focus - Zhang Jianping has heavily invested in the AI industry chain, robotics, and new energy sectors [1]. - His investments include: - Zhejiang Rongtai, which is involved in the core components of humanoid robots and has a leading position in the new energy sector [3]. - Rongtai's stock price has increased significantly due to its strategic acquisitions and market positioning [3]. - Hanwei Technology, a well-known sensor company, has also seen a price increase of over 154% this year [8]. Group 3: Strategic Moves - Zhang Jianping has shown a strong commitment to Cambrian, increasing his holdings despite stock price fluctuations, with a total of 608.63 million shares held [10][11]. - Cambrian's performance has been impressive, with a revenue increase of 4347.82% year-on-year, leading to a net profit of 1.038 billion yuan [15]. - The investment strategy includes a focus on emerging technologies and sectors, such as humanoid robots and embodied intelligence [7][8].

Core Viewpoint - The article highlights the significant investments made by Zhang Jianping in humanoid robots, AI sectors, and new energy, with a total holding value of approximately 5.096 billion yuan across nine A-share listed companies as of June 30 this year [2] Group 1: Investment Focus - Zhang Jianping has heavily invested in the AI industry chain, humanoid robots, and new energy sectors, with notable stock performances exceeding 200% and 100% year-to-date [2][4] - The stocks that Zhang Jianping has newly acquired in Q2 include Zhejiang Rongtai, Rongtai Co., Longxi Co., and others, which have shown significant price increases [5][9] Group 2: Stock Performance - Zhejiang Rongtai, with a holding of 1,091.26 million shares valued at 5.05 billion yuan, has seen a price increase of over 287% this year, with a nearly 87% rise in Q3 alone [5][11] - Rongtai Co. has also performed well, with a year-to-date increase of approximately 196% [9] - Longxi Co. has been involved in the humanoid robot sector and has experienced a price increase of around 195.64% this year [9] - Hanwei Technology, another stock in Zhang's portfolio, has increased by over 154% year-to-date [13] Group 3: AI Sector Investments - Zhang Jianping's major investment in the AI sector is represented by Cambricon Technologies, which has a holding value of 36.61 billion yuan and has seen a stock price increase of 196.81% in a short period [16][20] - Cambricon Technologies reported a significant revenue increase of 4,347.82% year-on-year, achieving a net profit of 1.038 billion yuan, marking a turnaround from losses [20] - The company Huibo Yuntong, also part of Zhang's investments, has seen a price increase of approximately 155% this year, with a notable acquisition planned to enhance its AI capabilities [20]

证券日报网讯9月2日晚间，长阳科技发布公告称，公司董事会同意聘任王敏女士为公司副总经理。 ...

证券代码：688299 证券简称：长阳科技 公告编号：2025-045 宁波长阳科技股份有限公司 关于聘任高级管理人员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 宁波长阳科技股份有限公司（以下简称"公司"）于 2025 年 9 月 2 日召开 第四届董事会第六次会议，审议通过了《关于聘任公司高级管理人员的议案》， 根据《中华人民共和国公司法》 券交易所科创板上市公司自律监管指引第 1 号——规范运作》等法律、法规以及 《宁波长阳科技股份有限公司章程》等相关规定，现将相关情况公告如下： 公司董事会同意聘任王敏女士（简历详见附件）为公司副总经理，任期自董 事会审议通过之日起至第四届董事会届满之日止。 本议案在提交董事会审议前，王敏女士的任职资格已经公司第四届董事会提 名委员会审核通过。王敏女士具备相关专业知识和工作经验，具备履行相关职责 的能力和任职条件。 特此公告。 宁波长阳科技股份有限公司董事会 《上海证券交易所科创板股票上市规则》 附件： 王敏女士，1972 年 9 月出生，博士研究生学历，正高级工程师，中国 ...

关于聘任高级管理人员的公告 证券代码：688299 证券简称：长阳科技 公告编号：2025-045 宁波长阳科技股份有限公司 特此公告。 宁波长阳科技股份有限公司董事会 2025 年 9 月 3 日 附件： 王敏女士，1972 年 9 月出生，博士研究生学历，正高级工程师，中国国籍， 无境外永久居留权。1996 年至 1998 年任中国计量大学教师；2002 年至 2018 年 历任通用电气中国技术中心研发科学家、陶氏化学技术支持及应用开发资深专家、 Styron 亚太区医疗应用开发经理、霍尼韦尔综合技术（中国）有限公司亚太区尼 龙树脂和化学品部高级技术经理、塞拉尼斯（中国）控股有限公司亚太区技术与 创新高级经理；2019 年加入富海集团，历任富海研究院院长、富海（东营）新 材料科技有限公司总经理、富海（东营）技术服务有限公司总经理、富海集团（上 海）新材料科技有限公司总经理、富海化工新材料总工程师等职。2025 年 8 月 加入公司，现任公司研究院院长。 王敏女士未直接或间接持有公司股份，与公司控股股东及实际控制人、持有 公司 5%以上股份的股东和公司董事、监事、其他高级管理人员不存在关联关系， 未受过中国 ...

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., received FDA approval for its self-developed biosimilar injection of Dexamethasone (HLX14) in two specifications: 60mg/mL and 120mg/1.7mL [2] Group 1 - The biosimilar product HLX14 has been granted a Biologics License Application (BLA) by the FDA [2]